CLBT vs NOVT: fair value comparison
Cellebrite DI Ltd. and Novanta Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Technology, NOVT currently sits closer to the top of our discount ranking. CLBT carries the stronger quality grade.
| CLBT | NOVT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $15.07 | $148.34 |
| 12-month range | $13.35–$18.50 | $100.82–$163.70 |
| Sector rank | #76 of 199 Technology | #71 of 199 Technology |
| Quality grade | A | D |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: CLBT fair value analysis · NOVT fair value analysis